This is supported by results from an ACCORD-Lipid sub-study, in which fenofibrate similarly lowered non-fasting TG in all T2DM participants, while reducing postprandial apoB48 excursions only in individuals with elevated fasting TG at baseline, a subgroup in which fenofibrate reduced CV outcomes [35]. This evidence concerns the gene APOB and type 2 diabetes mellitus.